MX2023001702A - Dosificacion y administracion de anticuerpos anti-c5 para el tratamiento de la microangiopatia trombotica asociada al trasplante de celulas madre hematopoyeticas (hsct-tma). - Google Patents
Dosificacion y administracion de anticuerpos anti-c5 para el tratamiento de la microangiopatia trombotica asociada al trasplante de celulas madre hematopoyeticas (hsct-tma).Info
- Publication number
- MX2023001702A MX2023001702A MX2023001702A MX2023001702A MX2023001702A MX 2023001702 A MX2023001702 A MX 2023001702A MX 2023001702 A MX2023001702 A MX 2023001702A MX 2023001702 A MX2023001702 A MX 2023001702A MX 2023001702 A MX2023001702 A MX 2023001702A
- Authority
- MX
- Mexico
- Prior art keywords
- hsct
- tma
- stem cell
- hematopoietic stem
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063065107P | 2020-08-13 | 2020-08-13 | |
| PCT/US2021/045823 WO2022036151A1 (en) | 2020-08-13 | 2021-08-12 | Dosage and administration of anti-c5 antibodies for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023001702A true MX2023001702A (es) | 2023-03-09 |
Family
ID=77655658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023001702A MX2023001702A (es) | 2020-08-13 | 2021-08-12 | Dosificacion y administracion de anticuerpos anti-c5 para el tratamiento de la microangiopatia trombotica asociada al trasplante de celulas madre hematopoyeticas (hsct-tma). |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240209071A1 (https=) |
| EP (1) | EP4196161A1 (https=) |
| JP (2) | JP7821160B2 (https=) |
| KR (1) | KR20230047179A (https=) |
| CN (1) | CN116249550A (https=) |
| AU (1) | AU2021326526B2 (https=) |
| CA (1) | CA3173007A1 (https=) |
| IL (1) | IL300115A (https=) |
| MX (1) | MX2023001702A (https=) |
| WO (1) | WO2022036151A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120035450A (zh) | 2022-09-06 | 2025-05-23 | 阿雷克森制药公司 | 造血干细胞移植物相关血栓性微血管病（hsct-tma）患者的诊断和预后生物标志物谱 |
| TW202426048A (zh) | 2022-09-06 | 2024-07-01 | 美商阿雷希昂製藥公司 | 用於治療造血幹細胞移植相關血栓性（ｈｓｃｔ－ｔｍａ）的抗ｃ５抗體的補充劑量和投與 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| PY09026846A (es) | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| JP6654137B2 (ja) * | 2013-09-16 | 2020-02-26 | チルドレンズ ホスピタル メディカル センター | Ｈｓｃｔ関連血栓性微小血管症の治療のための組成物及び方法 |
| NZ631007A (en) * | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| CN107207607B (zh) | 2014-12-19 | 2021-05-04 | 中外制药株式会社 | 抗-c5抗体及使用方法 |
| JP2019517473A (ja) * | 2016-05-27 | 2019-06-24 | アレクシオン ファーマシューティカルズ インコーポレイテッドＡｌｅｘｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 難治性全身型重症筋無力症の処置のための方法 |
| ES2984352T3 (es) | 2016-06-14 | 2024-10-29 | Regeneron Pharma | Anticuerpos anti-C5 y usos de los mismos |
| CA3080187A1 (en) * | 2017-10-26 | 2019-05-02 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) |
| JP7577542B2 (ja) | 2018-06-04 | 2024-11-05 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与 |
| JP2023522208A (ja) * | 2020-04-16 | 2023-05-29 | アシスタンス ピュブリック－オピト ド パリ | ウイルスによって引き起こされる補体媒介性障害を処置する方法 |
-
2021
- 2021-08-12 IL IL300115A patent/IL300115A/en unknown
- 2021-08-12 US US18/018,936 patent/US20240209071A1/en active Pending
- 2021-08-12 KR KR1020237008325A patent/KR20230047179A/ko active Pending
- 2021-08-12 JP JP2023509698A patent/JP7821160B2/ja active Active
- 2021-08-12 CA CA3173007A patent/CA3173007A1/en active Pending
- 2021-08-12 MX MX2023001702A patent/MX2023001702A/es unknown
- 2021-08-12 WO PCT/US2021/045823 patent/WO2022036151A1/en not_active Ceased
- 2021-08-12 AU AU2021326526A patent/AU2021326526B2/en active Active
- 2021-08-12 CN CN202180050198.2A patent/CN116249550A/zh active Pending
- 2021-08-12 EP EP21766299.8A patent/EP4196161A1/en active Pending
-
2025
- 2025-11-26 JP JP2025204019A patent/JP2026026191A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022036151A1 (en) | 2022-02-17 |
| IL300115A (en) | 2023-03-01 |
| JP2026026191A (ja) | 2026-02-16 |
| JP2023539047A (ja) | 2023-09-13 |
| AU2021326526B2 (en) | 2025-12-11 |
| KR20230047179A (ko) | 2023-04-06 |
| EP4196161A1 (en) | 2023-06-21 |
| US20240209071A1 (en) | 2024-06-27 |
| AU2021326526A1 (en) | 2023-03-02 |
| JP7821160B2 (ja) | 2026-02-26 |
| CN116249550A (zh) | 2023-06-09 |
| CA3173007A1 (en) | 2022-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4424324A3 (en) | Dosage and administration of anti-c5 antibodies for treatment of patients with membranoproliferative glomerulonephritis | |
| MX2020008882A (es) | Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1. | |
| BR112019008010A2 (pt) | anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica | |
| PH12021500031A1 (en) | Anti-il2 receptor gamma antigen-binding proteins | |
| CR20220646A (es) | Anticuerpos contra el sars-cov-2 y métodos de selección y uso de los mismos | |
| WO2007092939A8 (en) | Antigenic gm-csf peptides and antibodies to gm-csf | |
| MX2022008255A (es) | Anticuerpo anti-il-13 para usarse en el tratamiento de esofagitis eosinofilica. | |
| MX2023001702A (es) | Dosificacion y administracion de anticuerpos anti-c5 para el tratamiento de la microangiopatia trombotica asociada al trasplante de celulas madre hematopoyeticas (hsct-tma). | |
| SA523451800B1 (ar) | Sirp أجسام مضادة لـ ألفا | |
| MX2022005249A (es) | Anticuerpos anti-cd45 y conjugados de los mismos. | |
| MX2023002541A (es) | Anticuerpo biespecifico contra el cumulo de diferenciacion 3 (cd3) y el cumulo de diferenciacion 20 (cd20) en terapia combinada para el tratamiento del linfoma difuso de celulas b grandes. | |
| MY206214A (en) | Monoclonal antibodies that bind specifically to human trbv9 | |
| MX2023002106A (es) | Anticuerpos fgfr3 y metodos de uso. | |
| EA202091974A1 (ru) | Связывающие bcma антитела и их применение | |
| MX2023004806A (es) | Anticuerpos anti-tnf-a vectorizados para indicaciones oculares. | |
| MX2025004652A (es) | Conjugados de farmaco-anticuerpo del cumulo de diferenciacion (cd70) y metodos de uso de los mismos | |
| MX2022006148A (es) | Metodos para tratamiento del cancer usando anticuerpos anti-ox40 en combinacion con anticuerpos anti-tigit. | |
| BR112023026111A2 (pt) | Anticorpo anti-cd40, fragmento de ligação ao antígeno e uso médico do mesmo | |
| JOP20240280A1 (ar) | علاجات مشتركة باستخدام جسم مضاد لعامل xi/عامل xia | |
| BR112021015479A2 (pt) | Anticorpos anti-trem1 e métodos relacionados | |
| BR112021024328A2 (pt) | Métodos e composições para tratar doenças autoimunes | |
| MX2023015073A (es) | Dosificacion y administracion de anticuerpos anti-c5 para el tratamiento de la dermatomiositis (dm). | |
| MX2023003256A (es) | Dosificacion y administracion de anticuerpos anti-c5 para tratar la glomerulonefritis (gn) mediada por c5, incluyendo la nefritis lupica (nl) y/o la nefropatia por iga (niga). | |
| SE2515319A1 (en) | Bcma-targeted car-t cell therapy for multiple myeloma | |
| MX2023002852A (es) | Terapia de combinacion para el cancer. |